Washington, D.C. 20549


Form 8-K


Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported):  September 12, 2017



(Exact name of registrant as specified in its charter)


Nevada   001-38193   46-4744124

(State or other jurisdiction of



(Commission File Number


  (IRS Employer Identification No.)





201 Santa Monica Boulevard, Suite 500,

Santa Monica, CA




(Address of Principal Executive Offices)


  (Zip Code)


(310) 598-5410

Registrant’s telephone number, including area code

(Former name or former address if changed since last report,)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company x


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨








Item 7.01Regulation FD Disclosure.


Dr. Roger Crystal, the Chief Executive Officer of Opiant Pharmaceuticals, Inc. (the “Company”), shared a corporate presentation with potential investors of the Company on September 12, 2017 (the “Investor Presentation”) at the 2017 Rodman & Renshaw Global Investment Conference. A copy of the slides comprising the Investor Presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K.


In accordance with General Instruction B.2 on Form 8-K, the information set forth in this Item 7.01 and the Investor Presentation slides, attached to this report as Exhibit 99.1, are “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended.


Please refer to Exhibit 99.1 for a discussion of certain forward-looking statements included therein and the risk and uncertainties related thereto.


Item 9.01Financial Statements and Exhibits.


(d) Exhibits


Exhibit No. Description
99.1 Opiant Pharmaceuticals, Inc. September 2017 Company Presentation.








Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


    Opiant Pharmaceuticals, Inc.
Date: September 12, 2017 By: /s/ Dr. Roger Crystal
    Name: Dr. Roger Crystal
    Title: Chief Executive Officer





Exhibit 99.1 


FOCUSED ON ADDICTION Company Presentation September 2017 NASDAQ: OPNT



Forward Looking Statement 2 This presentation contains ‘forward - looking statements’ within the meaning of Section of the Securities Act of 1933 as amended, and Section 21E of the Securities Exchange Act of 1934 as amended. These forward - looking statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward - looking statements. In some cases, you can identify forward - looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” or “continue” or the negative of such terms and other comparable terminology. These forward - looking statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these forward - looking statements. Actual events or results may differ materially. In evaluating these forward - looking statements, you should specifically consider various factors. These and other factors may cause our actual results to differ materially from any forward - looking statement. We undertake no obligation to update any of the forward - looking statements after the date of this presentation to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.



3 OPNT: Focused on Addiction A Commercial - Stage Specialty Pharma Company Focused on Addiction Leveraging expertise, technology and a record of success to address the leading sources of addiction • Opioids • Alcohol • Food



4 Lead Programs Indication Product Candidate / Regulatory Pathway Pre - clinical Phase 1 Phase 2 Phase 3 NDA FDA Approval Partner Opioid Overdose NARCAN® Nasal Spray 505(b)(2) Eating Disorders OPNT001 Opioid Antagonist Nasal Spray 505(b)(2) Alcohol Dependence OPNT002 Opioid Antagonist Nasal Spray / 505(b)(2) Heroin Vaccine Heroin hapten + liposome adjuvant



Arvind Agrawal MSc EVP, Medical Affairs Extensive addiction and CNS drug development experience Dr. Roger Crystal MD MRCS MBA Chief Executive Officer David O’Toole , CPA Chief Financial Officer Mark Ellison, Ph.D. EVP Development, Manufacturing and Quality Dr. Phil Skolnick Ph.D   D.Sc  hon  Chief Scientific Officer Quan Vu VP, Corporate Development 5 Photo coming soon SM1



Opiant aims to become a leading addiction biopharma developing drugs at low cost, and quick to market Replicate recent success Invest long term Deliver on first program • New programs • predominantly 505(b)(2), relatively low cost , low technical risk • primarily using nasal opioid antagonists • Larger markets – chronic use • Earlier stage opportunities with novel modes of action x NARCAN® Nasal Spray FDA approved, licensed and commercialized, from concept to market in under 3 years 6



7 Addressing Addiction



8 Addiction has evolved as a disease, and now more acceptable to treat with pharmacotherapy The Past: Addicts as “junkies”; The Present: Addiction now recognized as a brain disease The Future: Incorporate pharmacotherapy as standard of care



Addiction now represents an attractive commercial opportunity 9 Strong sales from existing products • Suboxone sales > $1B • 27% growth in Vivitrol sales expected for 2017 - $250M Significant unmet need & increased government funding • Only 1 in 9 addicts receive appropriate treatment • Problem growing because of increased availability of heroin, fentanyl and related synthetics



10 Addictions are driven by the brain’s reward center releasing dopamine which can be blocked by opioid antagonists



Opioid antagonists acts on both the brain’s breathing and reward centers 11 Prior to OPNT001 2 time points after nasal administration of OPNT001



12 Opioid antagonists have been validated as therapeutics with an excellent safety profile



NARCAN® Nasal Spray 13



14 Opioid addiction and overdose: A significant public health crisis • Opioid overdose deaths have increased dramatically since 2000 • Dramatic increase in synthetic opioids including fentanyl • Approximately opioid 33,000 overdose deaths in 2015



A major issue is the rise in overdose cases from opioids more potent and longer lasting than heroin 15 Increasing overdose rates from 1. more potent opioids 2. longer acting opioids



16 Naloxone saves lives if given quickly – injections can only be given by qualified personnel Dial 911 Await ambulance Patient already stopped breathing Help often arrives too late Opioid pain killers, heroin, or fentanyl: victim unresponsive( ± breathing)



17 NARCAN® Nasal Spray is the only FDA - approved naloxone nasal spray for reversal of opioid overdose • Developed by Opiant • 2 doses now FDA approved • 6 FDA Orange Book patents • Licensed to Adapt Pharma in 2014 • Partial monetization deal with SWK: • OPNT received $17.5M, SWK receive next $26.25M royalties and milestones from Adapt • 1H 2017 – net sales were at least $25M • If 2017 net sales hit $55 - $75M, OPNT likely to receive royalty and milestones again from Adapt in 2018



18 NARCAN® Nasal Spray: Rapid absorption with higher blood levels compared to 0.4mg injectable naloxone Time Post Administration (hour) Naloxone Concentration (ng/ml) Dose 3 – 0.4mg Intramuscular Dose 1 – 4mg Intranasal Dose 2 – 2mg Intranasal 6.0 5.0 4.0 3.0 2.0 1.0 0.0 0.0 0.5 1.0 1.5 2.0 2.5 3.0



19 NARCAN® Nasal Spray – Easiest to use, needle free and among the least expensive Injectable Naloxone Autoinjectors Improvised Nasal Kits NARCAN® Nasal Spray • Only suitable for trained personnel • Requires prep time • Requires a needle • Expensive • Not needle free • Only suitable for trained personnel • Requires assembly • Not FDA - approved • Poor absorption • Single - use, multi - directional device • Easy to use • Rapid absorption



20 Over 20 million unique opioid users resulting in a potential $2B addressable market in U.S. *Opiant estimate of average selling price ** Co - prescribing starting to happen – mandatory in Vermont for high risk patients First Responders 1M patients with opioid use disorder taking methadone, suboxone etc. 20M Prescription Opioid Users – requiring co - prescribing NARCAN® Nasal Spray** x $100 per pack* = ~$2B Addressable Market Mandatory co - prescribing already in Vermont and Virginia for high risk patients ~$2B Addressable Market



21 NARCAN® Nasal Spray is becoming the mainstream rescue product across the USA



Beyond Overdose … .Addressing Chronic Treatment of Addictions 22



Opiant is leveraging NARCAN® success to address larger, broader addiction markets 12M 1.5M Opioid Overdose ~33k deaths per year Alcohol Use Disorder ~16 million Eating Disorders ~10 million Opioid Use Disorder ~2.4 million ACUTE CHRONIC 23



OPNT002 for Alcohol Use Disorder (AUD) 24



Today’s AUD medication requires abstinence and is poorly tolerated, so fewer than 5% of receive pharmacotherapy 25 patients with AUD currently receiving pharmacotherapy patients with AUD seeking treatment individuals in the USA meeting DSM - V diagnostic criteria for AUD 2.2M 15.7M 0.4M More effective pharmacotherapy – expected to increase # patients taking medication According to the CDC, AUD has annual cost of over $200 billion of which healthcare related costs are over $20 billion



Combining targeted dosing with a harm reduction endpoint, OPNT002 will be a differentiated product for AUD 26 Need for abstinence prior to commencing medication Need for abstinence as only acceptable outcome Low adherence for existing medication OPNT002 taken whenever patients have the urge to drink Existing pharmacotherapies for AUD OPNT002 FDA accept harm reduction as an outcome measure for OPNT002 ‘On demand’ dosing regimen – improved compliance expected



Faster nasal absorption vs oral Absorption of oral naltrexone is minimal at 5 - 10 minutes Rapid nasal absorption Vs oral, ensures that the maximum amount of drug is present when it is most needed 27 • Opioid receptors blocked when drinking alcohol • Patients can reduce heavy drinking Naltrexone blood levels: Oral Vs Nasal Vs Nasal with Intravail Nasal naltrexone absorption improved with Intravail



28 OPNT Existing Pharmacotherapies Criteria NASAL Naltrexone OPNT002 * Acamprosate (CAMPRAL) Disulfiram (ANTABUSE) Naltrexone HCl (Oral: ReVia ® / Generics) Naltrexone HCl (Injection: Vivitrol ®) “As - needed” use basis ✔ ✘ ✘ Can be used this way, but not current US practice ✘ Well - tolerated ✔ ✔ ✘ ✘ ✔ Safety ✔ − − ✔ ✔ Craving impact potential ✔ ✘ ✘ ✘ ✘ Long - term harm reduction potential  safe drinking ✔ ✘ ✘ ✘ ✘ No withdrawal required ✔ ✘ ✘ ✘ ✘ Approved drugs for Alcohol Use Disorder have limitations, which has limited their commercial success *Based on company expectations



29 Reduction in drinking improves mortality and is now an acceptable outcome measure for FDA approval



Taken as needed, avoiding detox, OPNT002 can transform AUD treatment & access AUD patients in several settings 30 Avoids the need for detox, withdrawal Patients take the drug when needed – greater control over drinking Reduce drinking rather than abstinence (accepted by FDA, KOLs) AUD patients in treatment centers AUD patients in primary care Population management – ability to reduce drinking within a whole healthcare system such as Kaiser



31 FDA feedback supportive of OPNT002 development plan alongside attractive commercial opportunity • Further development planned for 2H 2017 • 505(b)(2) regulatory pathway confirmed – increased likelihood and speed for FDA approval • Potential to self - commercialize and target treatment centers • Market dominated by generic competition – branded drug could rapidly gain market share



OPNT001 for Eating Disorders 32



Eating disorders affect millions with only one drug approved in each indication 33 Bulimia Nervosa • Compulsive bingeing and purging • Severe complications if untreated • Fluoxetine only approved drug • Affects 2.5M people in USA • Mostly young women Binge Eating Disorder • Most common eating disorder (8M in USA) • Food and food “cues” activate brain reward system • Shire’s Vyvanse® only approved drug (controlled substance)



164.8 171.3 174.8 179.9 188.6 199.9 0 - 40 - 80 - 120 - 160 - 180 Base 1 - 20 - 60 - 100 - 140 2 3 4 5 6 OPNT001 shows promise for Binge Eating Disorder 34 Proof of concept study (Helsinki) • (n=127) in patients with BED, Randomized, double blind, placebo controlled study • Significant reduction from baseline in bingeing after 6 months with OPNT001 compared to placebo (125 vs 84 mins per week; p=0.024 – per protocol) Placebo Weekly time (min) spent in binge eating, OPNT001 group reduced time in binging significantly more (p<0.024) OPNT001 Months Time (minutes) American Psychiatry Association Poster Presentation May 2013



OPNT001 Phase 2 trial design for Bulimia Nervosa 35 • Randomized, double blind, placebo controlled study in the UK underway • 80 patients • Primary endpoint – reduction in binge eating days • Expected duration – 12 months (further guidance once patient recruitment underway) • Data readout expected Q2 2018 • Bulimia being evaluated for self - commercialization



36 Corporate



37 Corporate/Clinical Milestones Enhance corporate governance through establishment of Board committees (1Q 2017) Initiate of Phase 2 trial of OPNT001 in Bulimia Nervosa (2Q 2017) Listed on Nasdaq Capital Market Strengthen management team through appointment of a CSO (1Q 2017) Ongoing development of OPNT 002 Alcohol Use Disorder program (2H 2017) Monetize NARCAN® Nasal Spray royalty (4Q 2016) Phase 2 Bulimia Nervosa data – expected 1H 2018



38 OPNT: Investment Highlights Record of commercialization in addiction, where others have failed High value pipeline, clinical and regulatory success in developing nasally - delivered opioid antagonists Significant competitive advantages and strong IP Strong partnerships and strengthened balance sheet Experienced management team with demonstrated ability to execute clinical programs